Literature DB >> 22114076

Deletion of the SPARC acidic domain or EGF-like module reduces SPARC-induced migration and signaling through p38 MAPK/HSP27 in glioma.

Heather M McClung1, William A Golembieski, Chad R Schultz, Michelle Jankowski, Lonni R Schultz, Sandra A Rempel.   

Abstract

We previously demonstrated that secreted protein acidic and rich in cysteine (SPARC) increases heat shock protein 27 (HSP27) expression and phosphorylation and promotes glioma cell migration through the p38 mitogen-activated protein kinase (MAPK)/HSP27 signaling pathway. As different regions of the SPARC protein mediate different SPARC functions, elucidating which SPARC domains regulate HSP27 expression, signaling and migration might provide potential therapeutic strategies to target these functions. To investigate the roles of specific domains, we used an SPARC-green fluorescent protein (GFP) fusion protein and constructs of SPARC-GFP with deletions of either the acidic domain (ΔAcidic) or the epidermal growth factor (EGF)-like module (ΔEGF). GFP, SPARC-GFP and the two deletion mutants were expressed in U87MG glioma cells. Characterization of the derived stable clones by confocal imaging and western blotting suggests proper folding, processing and secretion of the deletion constructs. Uptake of the constructs by naive cells suggests enhanced internalization of ΔAcidic and reduced internalization of ΔEGF. Wound and transwell migration assays and western blot analysis confirm our previous results and indicate that ΔAcidic reduces SPARC-induced migration and p38 MAPK/HSP27 signaling and ΔEGF decreases SPARC-induced migration and dramatically decreases the expression and phosphorylation of HSP27 but is poorly internalized. Loss of the EGF-like module suppresses the enhanced HSP27 protein stability conferred by SPARC. In conclusion, deletions of the acidic domain and EGF-like module have differential effects on cell surface binding and HSP27 protein stability; however, both regions regulate SPARC-induced migration and signaling through HSP27. Our data link the domains of SPARC with different functions and suggest one or both of the constructs as potential therapeutic agents to inhibit SPARC-induced migration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22114076      PMCID: PMC3271264          DOI: 10.1093/carcin/bgr276

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  54 in total

1.  SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity.

Authors:  Thomas H Barker; Gretchen Baneyx; Marina Cardó-Vila; Gail A Workman; Matt Weaver; Priya M Menon; Shoukat Dedhar; Sandra A Rempel; Wadih Arap; Renata Pasqualini; Viola Vogel; E Helene Sage
Journal:  J Biol Chem       Date:  2005-08-22       Impact factor: 5.157

Review 2.  Is SPARC an evolutionarily conserved collagen chaperone?

Authors:  N Martinek; J Shahab; J Sodek; M Ringuette
Journal:  J Dent Res       Date:  2007-04       Impact factor: 6.116

3.  MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27.

Authors:  Chunlei Zheng; Ziyang Lin; Zhizhuang Joe Zhao; Yajun Yang; Hanben Niu; Xun Shen
Journal:  J Biol Chem       Date:  2006-10-02       Impact factor: 5.157

4.  Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.

Authors:  Q Shi; S Bao; L Song; Q Wu; D D Bigner; A B Hjelmeland; J N Rich
Journal:  Oncogene       Date:  2007-01-08       Impact factor: 9.867

5.  Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues.

Authors:  T Ohnishi; S Hiraga; S Izumoto; H Matsumura; Y Kanemura; N Arita; T Hayakawa
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

6.  The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells.

Authors:  Anne Maglott; Petr Bartik; Sedat Cosgun; Philippe Klotz; Philippe Rondé; Guy Fuhrmann; Kenneth Takeda; Sophie Martin; Monique Dontenwill
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 7.  Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.

Authors:  Florence Lefranc; Jacques Brotchi; Robert Kiss
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

8.  Cell cycle-dependent nuclear location of the matricellular protein SPARC: association with the nuclear matrix.

Authors:  M D Gooden; R B Vernon; J A Bassuk; E H Sage
Journal:  J Cell Biochem       Date:  1999-08-01       Impact factor: 4.429

9.  Chaperone-like activity revealed in the matricellular protein SPARC.

Authors:  Ryan O Emerson; E Helene Sage; Joy G Ghosh; John I Clark
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

10.  Hsp27 regulates Akt activation and polymorphonuclear leukocyte apoptosis by scaffolding MK2 to Akt signal complex.

Authors:  Rui Wu; Hina Kausar; Paul Johnson; Diego E Montoya-Durango; Michael Merchant; Madhavi J Rane
Journal:  J Biol Chem       Date:  2007-05-17       Impact factor: 5.157

View more
  12 in total

1.  Adenovirus-mediated coexpression of DCX and SPARC radiosensitizes human malignant glioma cells.

Authors:  Yuanyuan Xu; Lei Yang; Xin Jiang; Jiahua Yu; Jicheng Yang; Haowen Zhang; Guomei Tai; Xiaopeng Yuan; Fenju Liu
Journal:  Cell Mol Neurobiol       Date:  2013-07-12       Impact factor: 5.046

2.  Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.

Authors:  Bin Wang; JiaQing Fang; Lei Qu; Zhongwei Cao; JianGuo Zhou; Biao Deng
Journal:  Tumour Biol       Date:  2015-04-08

Review 3.  Role of Matricellular Proteins in Disorders of the Central Nervous System.

Authors:  A R Jayakumar; A Apeksha; M D Norenberg
Journal:  Neurochem Res       Date:  2016-11-23       Impact factor: 3.996

4.  PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma.

Authors:  Ridwan Alam; Chad R Schultz; William A Golembieski; Laila M Poisson; Sandra A Rempel
Journal:  Neuro Oncol       Date:  2013-02-03       Impact factor: 12.300

Review 5.  Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.

Authors:  Daniel R Ciocca; Andre Patrick Arrigo; Stuart K Calderwood
Journal:  Arch Toxicol       Date:  2012-08-11       Impact factor: 5.153

6.  SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.

Authors:  Houda Alachkar; Ramasamy Santhanam; Kati Maharry; Klaus H Metzeler; Xiaomeng Huang; Jessica Kohlschmidt; Jason H Mendler; Juliana M Benito; Christopher Hickey; Paolo Neviani; Adrienne M Dorrance; Mirela Anghelina; Jihane Khalife; Somayeh S Tarighat; Stefano Volinia; Susan P Whitman; Peter Paschka; Pia Hoellerbauer; Yue-Zhong Wu; Lina Han; Brad N Bolon; William Blum; Krzysztof Mrózek; Andrew J Carroll; Danilo Perrotti; Michael Andreeff; Michael A Caligiuri; Marina Konopleva; Ramiro Garzon; Clara D Bloomfield; Guido Marcucci
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 7.  Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion.

Authors:  Jelena Grahovac; Alan Wells
Journal:  Lab Invest       Date:  2013-11-18       Impact factor: 5.662

8.  A holistic approach to dissecting SPARC family protein complexity reveals FSTL-1 as an inhibitor of pancreatic cancer cell growth.

Authors:  Katrina Viloria; Amanda Munasinghe; Sharan Asher; Roberto Bogyere; Lucy Jones; Natasha J Hill
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

9.  SPARC fusion protein induces cellular adhesive signaling.

Authors:  Lamei Cheng; E Helene Sage; Qi Yan
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

10.  HspB1, HspB5 and HspB4 in Human Cancers: Potent Oncogenic Role of Some of Their Client Proteins.

Authors:  André-Patrick Arrigo; Benjamin Gibert
Journal:  Cancers (Basel)       Date:  2014-02-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.